Metabolic profiling technologies for biomarker discovery in biomedicine and drug development

Pharmacogenomics

Volumn 7, Issue 7, 2006, Pages 1055-1075

  Schlotterbeck, Götz ^a   Ross, Alfred ^a   Dieterle, Frank ^b   Senn, Hans ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b NONE

Author keywords

Biofluid; Biomarker; Clinical; Mass spectrometry; Metabolic profiling; Metabolomics; Metabonomics; Nuclear magnetic resonance; Pharmaceutical; Statistical data analysis

Indexed keywords

BIOLOGICAL MARKER; HYDRAZINE;

ACCURACY; BIOMEDICINE; BLOOD ANALYSIS; CEREBROSPINAL FLUID ANALYSIS; DIAGNOSTIC PROCEDURE; DRUG RESEARCH; GAS CHROMATOGRAPHY; HUMAN; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; ION TRAP MASS SPECTROMETRY; LIPIDOSIS; LIQUID CHROMATOGRAPHY; LIVER TOXICITY; MAPLE SYRUP URINE DISEASE; MASS SPECTROMETRY; METABOLITE; METABOLOMICS; NEPHROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; PHENYLKETONURIA; QUADRUPOLE MASS SPECTROMETRY; REVIEW; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; SYSTEMS BIOLOGY; TOXICITY TESTING; URINALYSIS;

ANIMALS; BIOLOGICAL MARKERS; CHROMATOGRAPHY, GAS; DATA INTERPRETATION, STATISTICAL; DRUG DESIGN; GENE EXPRESSION PROFILING; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; METABOLISM; PHARMACOLOGY; SPECIMEN HANDLING;

EID: 33750480850     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.7.7.1055     Document Type: Review

References (193)

1. Pauling L, Robinson AB, Teranishi R, Cary P: Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. Proc. Natl. Acad Sci. USA 68, 2374-2376 (1971).
2. Webb KS, Lin GH: Urinary fibronectin - potential as a biomarker in prostatic-cancer. Investig. Urol. 17, 401-404 (1980).
3. Sorenson AW, Rosenshine N, Tepper SA, Kritchevsky D: Serum hexosaminidase as a possible biomarker for human cancer. J. Medicine 15, 409-415 (1984).
4. Phillips M, Gleeson K, Hughes JM et al.: Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Lancet 353, 2897-1898 (1999).
5. Phillips M, Cataneo RN, Ditkoff BA et al.: Volatile markers of breast cancer in the breath. Breast J. 9, 184-191 (2003).
6. Spanel P, Smith D, Holland TA, Al Singary W, Elder JB: Analysis of formaldehyde in the head space of urine from bladder and prostate cancer patients using selected ion flowtube mass spectrometry. Rapid Commun. Mass. Spectrom. 13, 1354-1359 (1999).
7. Glassbrook N, Ryals J: A systematic approach to biochemical profiling. Curr. Opin. Plant Biol. 4, 186-190 (2001).
8. Nicholson JK, Lindon JC, Holmes E: Metabonomics: understanding the metabolic responss of living systems to pathophysiological stimuli via multivariate statistical analysis of biologicla NMR spectroscopic data. Xenobiotica 29(11), 1181-1189 (1999).
9. Fiehn O: Metabolomics - the link between genotypes and phenotypes. Plant Mol. Biol. 48, 155-171 (2002).
10. Nicholson JK, Connelly J, Lindon JC, Holmes E: Metabonomics: a platform for studying drug toxicity and gene function. Nature Rev. Drug Disc. 1, 153-161 (2002).
11. Oliver SC, Winson MK, Kell DB, Baganz F: Systematic functional analysis of the yeast genome. Trends Biotech. 16, 373-378 (1998).
12. Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB: Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotech. 22, 245-252 (2004).
13. Watkins SM, German JB: Metabolomics and biochemical profiling in drug discovery and development. Curr. Opin. Mol. Ther. 4(3), 224-228 (2002).
14. Clayton TA, Lindon JC, Cloarec O et al.: Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440, 1073-1077 (2006).
15. Ernst RR, Bodenhausen G, Wokaun A: Principles of Nuclear Magnetic Resonance in One and Two Dimensions. Oxford University Press, Oxford, UK (1990).
16. Goldman M: Quantum Description of High-Resolution NMR in Liquids. Oxford University Press, Oxford, UK (1991).
17. Kovacs H, Moskau D, Spraul M: Cryogenically cooled probes - a leap in NMR technology. Prog. NMR Spectrosc. 46, 131-155 (2005).
18. 1H NMR-based metabonomic urinalysis. Chem. Res. Tox. 15, 1380-1386 (2002).
19. Prince WS: Water signal suppression in NMR spectroscopy. Ann. Rep. NMR Spectr. 38, 289-354 (1999).
20. Potts BC, Deese AJ, Stevens GJ, Reily MD, Robertson DG, Theiss J: NMR of biofluids and pattern recognition: assessing the impact of NMR parameters on the principal component analysis of urine from rat and mouse. J. Pharm. Biomed. Anal. 26, 463-76 (2001).
21. Hoult DI: Solvent peak saturation with single phase and quadrature Fourier transformation. J. Magn. Reson. 21, 337-347 (1976).
22. Kumar A, Ernst RR, Wüthrich K: A two-dimensional nuclear Overhauser enhancement (2D NOE) experiment for the elucidation of complete proton-proton cross-relaxation networks in biological macromolecules. Biochem. Biophys. Res. Commun. 95, 1-6 (1980).
23. 1H NMR spectroscopy. J. Magn. Reson. 104B, 1-10 (1994).
24. 1H NMR-based metabonomic study of urine and plasma samples obtained from healthy human subjects. J. Pharm. Biomed. Anal. 33, 1103-1115 (2003).
25. Meiboom S, Gill D.: Effects of diffusion on free precession in nuclear magnetic resonance experiments. Rev. Sci. Instrum. 29, 688-691 (1958).
26. Gibbs SJ, Johnson Jr CS: A PFG NMR experiment for accurate diffusion and flow studies in the presence of eddy currents. J. Magn. Reson. 93, 395-402 (1991).
27. Wider G, Dötsch V, and Wüthrich K: Self-compensating pulsed magnetic-field gradients for short recovery times. J. Magn. Reson. 108A, 255-258 (1994).
28. Morris KF, Johnson Jr CS: Diffusion-ordered two-dimensional nuclear magnetic resonance spectroscopy. J. Am. Chem. Soc. 114, 3139-3141 (1992).
29. 1H NMR spectroscopy. Magn. Reson. Med. 46, 249-255 (2001).
30. 1H NMR spectroscopic studies on intact rat renal cortex and medulla. Magn. Reson. Med. 41, 1108-1118 (1999).
31. 13C NMR spectroscopy of urine for metabonomic studies. Anal. Chem. 74, 4588-4593 (2002).
32. Boros LG, Brackett DJ, Harrigan GC: Metabolic biomarker and kinase drug target discovery in cancer using stable isotope-based dynamic metabolic profiling (SIDMAP). Curr. Cancer Drug Targets 3, 445-453 (2003).
33. 31P-NMR study. Biochem. J. 291, 915-919 (1993).
34. 13C] propionate, phenylacetate, and acetaminophen. Am. J. Physiol. 275, E843-E852 (1998).
35. 13C HMBC-NMR spectroscopy combined with pattern recognition procedures performed on filtered variables. Anal. Chem. 74, 2261-2273 (2002).
36. Günther H: NMR Spectroscopy. Wiley & Sons Inc. NY, USA (1992).
37. 1H NMR spectroscopy characterization of the complex metabolic pattern of urine from patients with inborn errors of metabolism: 2 hydroxyglutaric aciduria and maple syrup urine disease. J. Pharm. Biomed. Anal. 15, 1647-1659 (1997).
38. 1H-NMR spectroscopy of human cerebrospinal fluid: effects of sample manipulation and assignment of resonances. J. Pharm. Biomed. Anal. 11, 651-664 (1993).
39. Lynch MJ, Masters J, Pryor JP et al.: Ultra high field NMR spectroscopic studies on human seminal fluid, seminal vesicle and prostatic secretions. J. Pharm. Biomed. Anal. 12, 19-25 (1994).
40. 13C NMR spectroscopy of human blood plasma. Anal. Chem. 67, 793-811 (1996).
41. Bax A, Davis DG: MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopy. J. Magn. Reson. 65, 355-360 (1985).
42. Bax A, Freeman R: Investigation of complex networks of spin-spin coupling by two-dimensional NMR. J. Magn. Reson. 44, 542-561 (1981).
43. Derome A, Williamson M: Rapid-pulsing artifacts in double-quantum-filtered COSY. J. Magn. Reson. 88, 177-185 (1990).
44. Ancian B, Bourgeois I, Dauphin JF, Shaw AA: Artifact-free pure absorption PFG-enhanced DQF-COSY spectra including a gradient pulse in the evolution period. J. Magn. Reson. 125A, 348-354 (1997).
45. Nicholls AW, Holmes E, Lindon JC et al.: Metabonomic investigations into hydrazine toxicity in the rat. Chem. Res. Toxicol. 14, 975-987 (2001).
46. 13C magic angle spinning NMR spectroscopy of rat liver. Magn. Reson. Med. 42, 201-207 (2000).
47. 1H NMR spectroscopy of biological fluids. Anal. Chem. 68, 3370-3376 (1996).
48. Palmer III AG, Cavanagh J, Wright PE, Rance M: Sensitivity improvement in proton-detected two-dimensional heteronuclear correlation NMR spectroscopy. J. Magn. Reson. 93, 151-170 (1991).
49. Kay LE, Keifer P, Saarinen T: Pure absorption gradient enhanced heteronuclear single quantum correlation spectroscopy with improved sensitivity. J. Am. Chem. Soc. 114, 10663-10665 (1992).
50. Hurd RE, John BK: Gradient-enhanced proton-detected heteronuclear multiple-quantum coherence spectroscopy. J. Magn. Reson. 91, 648-653 (1991).
51. Bax A, Summers MF: Proton and carbon-13 assignments from sensitivity-enhanced detection of heteronuclear multiple-bond connectivity by 2D multiple quantum NMR. J. Am. Chem. Soc. 108, 2093-2094 (1986).
52. 1H nuclear magnetic resonance and high performance liquid chromatography. Biomarkers 8, 240-271 (2003).
53. Nicholls AW, Nicholson JK, Haselden JK, Waterfield CJ: A metabonomic approach to the investigation of drug-induced phospholipidosis: an NMR spectroscopy and pattern recognition study. Biomarkers 5, 410-423 (2000).
54. Hoch JC, Stern AS: NMR Data Processing. John Wiley & Sons Inc., NY, USA (1997).
55. Traficante DD, Rajabzadeh M: Optimum window function for sensitivity enhancement of NMR signals. Conc. Magn. Reson. 12, 83-101 (2000).
56. 1H NMR metabonomics. Anal. Chem. 78, 4281-4290 (2006).
57. Dieterle F, Ross A, Schlotterbeck G, Senn H: Metabolite projection analysis for fast identification of metabolites in metabonomics. application in an amiodarone study. Anal. Chem. 78, 3551-3561 (2006).
58. Schnackenberg L, Beger RD, Dragan Y: NMR-based metabonomic evaluation of livers from rats chronically treated with tamoxifen, mestranol, and phenobarbital. Metabolomics 1, 87-94 (2005).
59. Cañas-Montalvo B, López-Ferrer D, Ramos-Fernández A, Camafeita E, Calvo E: Mass spectrometry technologies for proteomics. Brief Funct. Genomic. Proteomic. 4, 295-320 (2006).
60. Glinski M, Weckwerth W: The roll of mass spectrometry in plant systems biology. Mass Spectrom. Rev. 25, 173-214 (2006).
61. Want EJ, Cravatt BF, Siuzdak G: The expanding role of mass spectrometry in metabolite profiling and characterization. ChemBioChem 6, 1941-1951 (2005).
62. Fiehn O, Kopka J, Dormann P, Altmann T, Trethewey RN, Willmitzer L: Metabolite profiling for plant functional genomics. Nat. Biotechnol. 18, 1157-1161 (2000).
63. Koek MM, Muilwijk B, van der Werf, MJ, Hankemeier T: Microbial metabolomics with gas chromatography/mass spectrometry. Anal. Chem. 78, 1272-1281 (2006).
64. Fiehn O: Combining genomic, metabolome analysis and biochemical modelling to understand metabolic networks. Comp. Funct. Genom. 2, 155-168 (2001).
65. Horning EC, Horning MG: Metabolic profiles: gas-phase methods for analysis of metabolites. Clin. Chem. 17, 802-809 (1971).
66. Niwa T: Metabolic profiling with gas chromatography-mass spectrometry and its application to clinical medicine. J. Chromatogr. 379, 313-345 (1986).
67. Rashed MS: Clinical applications of tandem mass spectrometry: ten years of diagnosis and screening for inherited metabolic diseases. J. Chromatogr. B. 758, 27-48 (2001).
68. Röschinger W, Olgemöller B, Fingerhut R, Liebl B, Roscher AA: Advances in analytical mass spectrometry to improve screening for inherited metabolic diseases. Eur. J. Pediatr. 162, 67-76 (2003).
69. Zytkovic TH, Fitzgerald EF, Marsden D et al.: Tandem mass spectrometric analysis for amino, organic and fatty acid disorders in newborn dries blood spots: a two-year summary from the New Egland Newborn Screening Program. Clin. Chem. 47, 1945-1955 (2001).
70. Levy HL, Albers S: Genetic screening of newborms. Annu. Rev. Genomics Hum. Genet. 1, 139 (2000).
71. Deng C, Wang B, Liu L: Fast diagnosis of neonatal phenylketonuria by gas chromatography-mass spectrometry following microwave-assisted silylation. Chromatographia 62, 617-621 (2005).
72. Shellie RA, Welthagen W, Zrostlikov J et al.: Statistical methods for comparing comprehensive two-dimensional gas chromatography-time-of-flight mass spectrometry results: metabolomic analysis of mouse tissue extracts. J. Chromatogr. A 1086, 83-90 (2005).
73. van Mispelaar VG, Tas AC, Smilde AK, Schoenmakers PJ, van Asten AC: Quantitative analysis of target components by comprehensive two-dimensional gas chromatography. J. Chromatogr. A 1019 15-29 (2003).
74. Electrospray Ionization Mass Spectrometry: Fundamentals, Instrumentation, and Applications. Cole RB (Ed.), Wiley, NY, USA (1997).
75. Gaskell SJ: Electrospray principles and practice. J. Mass Spectrom. 32, 677-688 (1997).
76. Niessen WMA: Progress in liquid chromatography-mass spectrometry instrumentation and ist impact on high-throughput screening. J. Chromatogr: A 1000, 413-436 (2003).
77. Pramanik BN, Ganguly AK, Gross ML: Applied Electrospray mass Spectrometry. Marcel Dekker, NY, USA (2002).
78. Wilson ID, Plumb R, Granger J, Major H, Williams R, Lenz EM: HPLC-MS based methods fort he study of metabonomics. J. Chromatogr. B817, 67-76 (2005).
79. Goodacre R, Vaidyanathan S, Bianchi G, Kell DB: Metabolic profiling using direct infusion electrospray ionisation mass spectrometry fort he characterisation of olive oil. Analyst 127, 1457-1462 (2002).
80. Tolstikov VV, Lommen A, Nakanishi K, Tanaka N, Fiehn O: Monolithic silica-based capillary reversed-phase liquid chromatography/electrospray mass spectrometry for plant metabolomics Anal. Chem. 75, 6737-6740 (2003).
81. Crockford DJ, Holmes E, Lindon JC et al.: Statistical heterospectroscopy, an approach to the integrated analysis of NMR and UPLC-MS data sets: application in metabonomic toxicology studies. Anal. Chem. 78, 363-371 (2006).
82. Nordström A, O'Maille G, Qin C, Siudzak G: Nonlinear data alignment for UPLC-MS and HPLC-MS based metabolomics: quantitative analysis of endogenous and exogenous metabolites in human serum. Anal. Chem. 78, 3289-3295 (2006).
83. Kapron JT, pace E, Van Pelt CK, Henion J: Quantitation of midazolam in human plasma by automated chip-based infusion nanoelectrospray tandem mass spectrometry. Rapid Commun. Mass Spectrom. 17, 2019-2026 (2003).
84. Leuthold LA, Grivet C, Allen M, Baumert M, Hopfgartner G: Simultaneous selected reaction monitoring. MS/MS and MS3 quantitation for the analysis of pharmaceutical compounds in human plasma using chip-based infusion. Rapid Commun. Mass Spectrom. 18, 1995-2000 (2004).
85. Boernsen KO, Gatzek S, Imbert G: controlled protein precipitation in combination with chip-based nanospray infusion mass spectrometry. An approach for metabolomics profiling of plasma. Anal. Chem. 77, 7255-7264 (2005).
86. Staack RF, Varesio E, Hopfgartner G: The combination of liquid chromatography/tandem mass spectrometry and chip-based infusion for improved screening and characterization of drug metabolites. Rapid Commun. Mass Spectrom. 19, 618-626 (2005).
87. Wang G, Hsieh Y, Korfmacher WA: Comparison of atmospheric pressure chemical ionization, electrospray ionization, and atmospheric pressure photoionization for the determination of cyclosporin A in rat plasma. Anal. Chem. 77, 541-548 (2005).
88. Raffaelli A, Saba A: Atmospheric pressure photoionization mass spectrometry, Mass Spectrom. Rev. 22, 318-331 (2003).
89. Robb DB, Covey TR, Bruins AP: Atmospheric pressure photoionization: an ionization method for liquid chromatography mass spectrometry. Anal. Chem. 72, 3653-3659 (2000).
90. Cody RB, Laramée JA, Durst HD: Versatile new ion source for the analysis of materials in open air under ambient conditions. Anal. Chem. 77, 2297-2302 (2005).
91. Morris HR, Paxton T, Dell A et al.: High sensitivity collisional-activated decomposition tandem mass spectrometry on a novel quadrupole/orthogonal-acceleration time-of-flight mass spectrometer. Rapid Commun. Mass Spectrom: 10, 889-896 (1996).
92. Cox KA, Higher throughput metabolite identification in drug discovery: current capabilities and future trends. Am. Pharm. Rev. 4, 45-22 (2001).
93. Hopfgartner G, Husser C, Zell M: Rapid screening and characterization of drug metabolites using a new quadrupole-linear ion trap mass spectrometer. J. Mass Spectrom. 38, 138-150 (2003).
94. Le Blanc JC, Hager JW, Illisiu AM et al.: Unique scanning capabilities of a new hybrid linear ion trial mass spectrometer (Q TRAP) used for high sensitivity proteomics applications. Proteomics 3, 859-869 (2003).
95. Syka JEP, Marto JA, Bai DL et al.: Novel linear quadrupole ion trap/FT mass spectrometer: performance characterization and use in the comparative analysis of histone H3 post-translational modifications. J. Proteome. Res. 3, 621-626 (2004).
96. Xia YQ, Miller JD, Bakhtiar R, Franklin RB, Liu DQ: Use of a quadrupole linear ion trap mass spectrometer in metabolite identification and bioanalysis. Rapid Commun. Mass Spectrom. 17, 1137-1145 (2003).
97. Makarov A, Denisov E, Lange O, Horning S: Dynamic range of mass accuracy in LTQ orbitrap hybrid mass spectrometer. J. Am. Soc. Mass Spectrom. 17, 977-982 (2006).
98. Martin SE, Shabanowitz J, Hunt DF, Marto JA: Subfemtomole MS and MS/MS peptide sequence analysis using nano-HPLC micro-ESI fourier transform ion cyclotron resonance mass spectrometry. Anal. Chem. 72, 4266-4274 (2000).
99. Plumb RS, Stump CL, Gorenastein MV et al.: Metabonomics: the use of electrospray mass spectrometry coupled to reversed-phase liquid chromatography shows potential fort he screening of rat urine in drug development. Rapid Commun. Mass Spectrom. 16, 1991-1996 (2002).
100. Vorst O, de Vos CHR, Lommen A et al.: A non-directed approach to differential analysis of multiple LC-MS-derived metabolic profiles. Metabolomics 1, 169-189 (2005).
101. Katjamaa M, Oresic M: Processing methods for differential analysis of LC/ MS profile data. BMC Bioinformatics 6, 179 (2005).
102. Idborg H, Zamani L, Edlund PO, Schuppe-Koistinen I, Jacobsson SP: Metabolic fingerprinting of rat urine by LC/MS Part 2. Data pretreatment methods for handling of complex data. J. Chromatogr. B 828, 14-20 (2005).
103. Idborg H, Edlund PO, Jacobsson SP: Multivariate approaches for efficient detection of potential metabolites from liquid chromatography/mass spectrometry data. Rapid Commun. Mass Spectrom. 18, 944-954 (2004).
104. Winding W, Phalp JM, Payne AW: A noise and background reduction method for component detection in liquid chromatography/mass spectrometry. Anal. Chem. 68, 3602-3606 (1996).
105. Halket JM, Przyborowska A, Stein SE, Mallard WG, Down S, Chalmers RA: Deconvolution gas chromatography/mass spectrometry of urinary organic acids - potential for pattern recognition and automated identification of metabolic disorders. Rapid Commun. Mass Spectrom. 13, 279-284 (1999).
106. Stolt, R, Torgrip RJO, Lindberg J et al.: Second-order peak detection for multicomponent high-resolution LC/MS data. Anal. Chein. 78, 975-983 (2006).
107. Duran AL, Yang J, Wang L, Summer LW: Metabolomics spectral formatting, alignment and conversion tools (MSFACTs). Bioinformatics 19, 2283-2293 (2003).
108. Smith CA, Want EJ, O'Maille G, Abagyan R, Siudzak G: XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal. Chem. 78, 779-787 (2006).
109. Broeckling CD, Reddy IR, Duran IR, Zhao X, Sumner LW: MET-IDEA: data extraction tool for mass spectrometry-based metabolomics. Anal. Chem. 78(13), 4334-4341. (2006).
110. Kopka J, Schauer N, Krueger S et al.: GMDΓSB.DB: the golm metabolome database. Bioinformatics 15, 1635-1638 (2005).
111. Smith CA, O'Maille G, Want EJ et al.: METLIN a metabolite mass spectral database. Ther. Drug Monit. 27, 747-751 (2005).
112. Holmes E, Nicholson JK, Nicholls AW et al.: The identification of novel biomarkers of renal toxicity using automatic data reduction techniques and PCA of proton NMR spectra of urine. Chemometr. Intell. Lab. 44, 245-255 (1998).
113. Forshed J, Schuppe-Koistinen I, Jacobsson SP: Peak alignment of NMR signals by means of a genetic algorithm. Anal. Chim. Acta 487, 189-199 (2003).
114. Waters NJ, Waterfield CJ, Farrant RD, Homes F, Nicholson JK: Metabonomic deconvolution of embedded toxicity: application to thioacetamide hepato- and nephrotoxicity. Chem. Res. Toxicol. 18, 639-654 (2005).
115. Jansen JJ, Hoefsloot HCJ, Boelens HFM, van der Greef J, Smilde AK: Analysis of longitudinal metabolomics data. Bioinformatics 20(15), 2438-2446 (2004).
116. Holmes E, Antti H: Chemometric contributions to the evolution of metabonomics: mathematical solutions to characterizing and interpreting complex biological NMR spectra. Analyst 127, 1549-1557 (2002).
117. Holmes E, Nicholls AW, Lindon JC et al.: Chemometric models for toxicity classification based on nmr spectra of biofluids. Chem. Res. Toxicol. 13, 471-478 (2000).
118. Kramer R: Chemometric techniques for quantitative analysis. Marcel Dekker Inc., NY, USA (1998).
119. Wold H: Nonlinear iterative partial least squares (NIPALS) modeling - some current developments. In: Multivariate Analysis. Krishnajah PR (Ed.), Academic Press, NY, USA (1973).
120. Martens H, Naes T: Multivariate Calibration. John Wiley & Sons Inc., NY, USA (1989).
121. Martens H, Martens H: Multivariate Analysis of Quality - An Introduction. John Wiley & Sons Inc., NY, USA(2000).
122. Esbensen KH: Multivariate Data Analysis - In Practice, Fifth Editon. Camo Process AS, Norway (2001).
123. 1H-NMR-based metabonomics. Nat. Med. 8, 1439-1444 (2002).
124. Gavaghan CL, Wilson ID, Nicholson JK: Physiological variation in metabolic phenotyping and functional genomic studies: use of orthogonal signal correction and PLS-DA. FEBS Letters, 530, 191-196 (2002).
125. Eriksson L, Antti H, Gottfies J et al.: Using chemometrics for navigating in the large data sets of genomics, proteomics and metabonomics (gpm). Anal. Bioanal. Chem. 380, 419-429 (2004).
126. Keun HC, Ebbels TMC, Antti H et al.: Improved analysis of multivariate data by variable stability scaling: application to NMR-based metabolic profiling. Anal. Chim. Acta 490, 265-276 (2003).
127. Antti H, Ebels TMD, Keun HC et al.: Statistical experimental design and partial least squares regression analysis of biofluid metabonomic NMR and clinical chemistry data for screening of adverse drug effects. Chemometr. Intell. Lab. 73, 139-149 (2004).
128. 1H NMR-derived urinary spectral data. J. Chemom. 16, 461-468 (2002).
129. 1H NMR spectroscopic metabonomics studies. Anal. Chem. 77(2), 517-526 (2005).
130. 1H NMR data sets. Anal. Chem. 77(5) 1282-1289 (2005).
131. Williams ID, Nicholson JK, Castrop J et al.: High resolution liquid chromatography coupled to a TOF mass spectrometry as a tool for differntial metabolic pathway profiling in functional genomic studies. J. Proteome. Res. 4(2), 591-598 (2005).
132. Wang C, Kong H, Guan Y et al.: Plasma Phospholipid metabolic profiling and biomarkers of type 2 diabetes mellitus based on electrospray mass spectrometry and multivariate statistical analysis Anal. Chem. 77(13), 4108-4116 (2005).
133. Williams RE, Lenz EM, Rantalainen M Wilson I: The comparative metabonomics of age-related changes in the urinary composition of male Wistar-derived and Zucker (fa/fa) obese rats. Mol. Biosyst. 2, 193-202 (2006).
134. Lenz EM, Bright J, Knight R, Wilson ID, Major H: Cyclosporin A-induced changes in endogenous metabolites in rat urine: a metabonomic investigation using high field 1H NMR spectroscopy, HPLCTOF/MS and chemometrics. J Pharm. Biomed Anal. 35, 599-608 (2004).
135. 1H NMR spectra of urine using an artificial neural network. J. Pharmaceut. Biomed. Anal. 13, 205-211 (1995).
136. Holmes E, Nicholson JK, Tranter G: Metabonomic characterization of genetic variations in toxicological and metabolic responses using probabilistic neural networks. Chem. Res. Tox. 14, 182-191 (2001).
137. Ebbels T, Keun H, Beckonert O et al.: Toxicity classification from metabonomic data using a density superposition approach: 'Clouds'. Anal. Chim. Acta 490, 109-122 (2003).
138. Beckonert O, Bollard ME, Ebbels TMD et al.: NMR-based metabonomic toxicity classification: hierarchical cluster analysis and k-nearest-neighbour approaches. Anal. Chim. Acta 490, 3-15 (2003).
139. Eads, CD, Furnish CM, Noda I, Juhlin KD, Cooper DA, Morrall SW: Molecular Factor Analysis Applied to Collections of NMR Spectra, Anal. Chem. 76(7), 1982-1990 (2004).
140. 1H spectra with LCModel. NMR Biomed. 14, 260-264 (2001).
141. 1H NMR: application in metabonomic toxicology studies. Anal. Chem. 77(14), 4556-4562 (2005).
142. Ogborn MR, Sareen S, Prychitko J, Buist R, Peeling J: Altered organic anion and osmolyte content and excretion in rat polycystic kidney disease: an NMR study. Am. J. Physiol, 272 (1-2), F63-F69 (1997).
143. Dieterle F, Schlotterbeck G, Ross A, Niederhauser U, Senn H: Application of metabonomics in a compound ranking study in early drug development revealing drug-induced application of metabonomics in a compound ranking study in early. Chem. Res. Toxicol. 19, 1175-1181 (2006).
144. 1H NMR-based metabonomic techniques to distinguish between HIV-1 positive/ AIDS patients on antiretroviral treatment and HIV-1 negative individuals. J. Pharm, Biomed. Anal. 41, 1442-1446 (2006).
145. 13C HMBC NMR metabonomics. J. Prot. Res. 4, 1493-1502 (2005).
146. Holland NT, Smith MT, Eskenazi B, Bastaki M: Challenges of biological sample collection and processing for large epidemiological projects. Mutat. Res. 543, 217-234 (2003).
147. 1H NMR spectroscopic analysis in toxicology studies to determine inherent variation in biochemical profiles. J. Pharm. Biomed. Anal. 30, 1297-1310 (2002).
148. COMET Consortium internal presentation, O Beckonert. COMET Steering Committee Meeting, Brussels, Belgium, 27-28 June, 2002: A new format for study reports (2002).
149. Ciba-Geigy AG (Ed.): Wissenschaftliche Tabellen Geigy, Volume 1, 8th Edition. Ciba-Geigy, Basel, Switzerland (1980).
150. Ross A, Schlotterbeck C, Dieterle F, Senn H: NMR spectroscopy in metabolic profiling. In: The Handbook of Metabonomics and Metabolomics. Chapter 3. Lindon JC, Nicholson JK, Holmes E (Eds.), Elsevier, Amsterdam (2006).
151. Vaz FM, Melegh B, Bene J et al.: Analysis of carnitine biosynthesis metabolites in urine by HPLC-electrospray tandem mass spectrometry. Clin. Chem. 48, 826-834 (2002).
152. Vernez L, Hopfgartner G, Wenk M, Krähenbühl S: Determination of carnitine and acylcarnitines in urine by high-performance liquid chromatography-electrospray ionization ion trap tandem mass spectrometry. J. Chromatogr. A 984, 203-213 (2003).
153. Zongmin D, Ruifu Y, Zhaobiao G, Yajun S, Jin W: Identification of Staphylococcus aureus and determination of its methicillin resistance by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal. Chem. 74, 5487-5491 (2002).
154. Want EJ, O'Maille G, Smith CA et al.: Solvent-dependent metabolite distribution, clustering, and protein extraction for serum profiling with mass spectrometry. Anal. Chem. 78, 743-752 (2006).
155. Drake SK, Bowen RAR, Remaley AT, Hortin GL: Potential interferences from blood collection tubes in mass spectrometric analyses of serum polypeptides. Clin. Chem. 50, 2398-2401 (2004).
156. Hsieh SY, Chen RK, Pan YH, Lee HL: Systematical evaluation of the effects of sample collection procedures on low-molecular-weight serum/ plasma proteome profiling. Proteomics 6, 3189-3198 (2006).
157. 1H nuclear magnetic resonance spectroscopy. Anal. Biochem. 304, 220-230 (2002).
158. 1H HR-MAS spectroscopy. Magn Reson Med. 55, 1257-1264 (2006).
159. Martinez-Granados B, Monleon D, Martinez-Bisbal MC et al.: Metabolite identification in human liver needle biopsies by high-resolution magic angle spinning 1H NMR spectroscopy. NMRB Bioomed. 19, 90-100 (2006).
160. 1H NMR spectroscopy. Anal. Chem. 77, 5570-5578 (2005)
161. Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS: Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed, 19, 30-40 (2006).
162. 1H NMR investigation of changes in the metabolic profile of synovial fluid in bilateral canine osteoarthritis with unilateral joint denervation. Osteoarthr. Cartil. 7, 165-172 (1999).
163. 1H NMR analysis as a diagnostic probe for human saliva. Biochem. Biophys. Res. Common. 329, 1-5 (2005).
164. Khandelwal P, Beyer CE, Lin Q, Schechter LE, Bach AC: Studying rat brain neurochemistry using nanoprobe NMR spectroscopy: a metabonomics approach. Anal. Chem., 76, 4123-4127 (2004).
165. Sanisns SM, Nicholson JK, Elcombe C, Timbrell JA: Hepatoxin-induced hypertaurinuria: a proton NMR study. Arch. Toxicol. 64, 407-411 (1990).
166. Nicholson JK, Highham DP, Timbrell JA, Sadler PJ: Quantitative high-resolution NMR urinalysis studies on the biochemical effects of cadmium in the rat. Mol. Pharmacol. 36, 398-404 (1989).
167. Robertson DG, Reily MD, Lindon JNC, Holmes E, Nicholson JK: Metabonomic, technology as a tool for rapid throughput in vivo toxicity screening. Compr. Toxicol. 14, 583-610 (2002).
168. Williams RE, Major H, Lock EA, Lenz EM, Wilson ID: D-serine induced nephrotoxicity - a metabonomics approach. Toxicology 207(2), 179-190 (2005).
169. Keun HC: Metabonomic modeling of drug toxicity. Pharmacol. Ther. 109, 92-106 (2006).
170. Lindon JC, Holmes E, Nicholson JK: Toxicological applications of magnetic resonance. Prog. Nucl. Magn. Reson. Spectrosc. 45(1-2), 109-143 (2004).
171. Lindon JC, Holmes E, Bollard ME, Stanley EG, Nicholson JK: Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers 9, 1-31 (2004).
172. Fung M, Thornton A, Mybeck K, Wu JH, Hornbuckle K, Muniz E: Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets - 1960 to 1999. Drug Inform. J. 35, 293-317 (2001).
173. Lindon JC, Keun HC, Ebbels TM, Pearce JM, Holmes, E, Nicholson JK: The consortium for metabonomic toxicology (COMET): aims, activities and achievments. Pharmacogenomics 6(7), 691-699 (2005).
174. Lindon JC, Nicholson JK, Holmes E et al.: Contemporary issues in toxicology: the role of metabonomics in toxicology and its evaluation by the COMET project, Toxicol. Appl. Pharmacol. 187(3), 137-146 (2003).
175. Reasor, MJ, Ogle CL, Walker ER, Kacew S: Amiadorone-induced phosholipidosis in rat alveolar macrophages. Am. Rev. Respir. Dis. 137, 510-518 (1998).
176. Kodavanti, UP, Mehendale HM: Cationic ambiphilic drugs and phospholipid storage disorders. Rharmacol. Rev. 42, 327-354 (1990).
177. Lullmann H, Lullmann-Rauch R, Wassermann O: Drug induced phospholipidosis. Crit. Rev. Toxicol. 2, 185-218 (1975)
178. Kodovanti UP, Lockhard VG, Mehendale HM: In vivo toxicity and pulmonary effects of promazine and chlorpromazine in rats. J. Biochem. Toxicol. 5, 245-251 (1990).
179. Espina, JR, Shockcor, J. Herron, W et al.: Detection of in vivo biomarkers of phospholipidosis using NMR-based metabonomic approaches. Magn. Reson. Chem. 39, 559-565 (2001).
180. Lindon JC, Nicholson JK, Everett JR: NMR spectroscopy of biofluids. In: Ann Reports NMR Spectr. Webb GA (Ed.), Academic Press, Oxford, UK, 38, 1-88 (1999).
181. Chace DH, Millington DS, Terada N, Kahler SG, Roe CR, Hofman LF: Rapid diagnosis of phenylketonuria by quantitative analysis for phenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry. Clin. Chem. 39, 66-71. (1993).
182. Garg, U, Dasouki M: Expanded newborn screening of inherited metabolic disorders by tandem mass spectrometry: clinical and laboratory aspects. Clin. Biochem. 39, 315-32 (2006).
183. Fingerhut R, Röschinger W, Muntau AC et al.: Hepatic carnitine palmitoyltransferase 1 deficiency: acylcarnitine profiles in blood spots are highly specific. Clin. Chem. 47, 1763-1768 (2001).
184. Pollitt RJ: International perspectives on newborn screening. J. Inherit. Metab. Dis. 29, 390-396 (2006).
185. Bathen TF, Krane J, Engan T, Bjerve KS, Axelson D: Quantification of plasma lipids and apolipoproteins by use of proton NMR spectroscopy, multivariate and neural network analysis. NMR Biomed. 13, 271-288 (2000).
186. Tsai MY, Georgopoulos A, Otvos JD et al.: Comparison of ultracentrifugation and the quantification of triglyceride rich lipoproteins after an oral fat load. Clin. Chem. 50, 1201-1204 (2004).
187. Freedman DS, Otvos JD, Jeyarajah EJ et al.: Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham study. Clin. Chem. 50, 1189-1200 (2004).
188. Ala-Korpela M, Korhonen A, Keisala J et al.: 1H NMR-based absolute quantitation of human lipoproteins and their lipid contents directly from plasma. J. Lip. Res. 35, 2292-2304 (1994).
189. Soedamah-Muthu SS, Chang YF, Otvos J, Evans RW, Orchard TJ: Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 46, 674-682 (2003).
190. Kuller L, Arnold A, Tracy R et al.: Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler. Thromb. Vasc. Biol. 22, 1175-1180 (2002).
191. Russo GT, Meigs JB, Cupples LA et al.: Association of the Sst-I polymorphism at the APOC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary heart disease risk: the Framingham offspring study. Atherosclerosis 158, 173-181 (2001).
192. Kochar S, Jacobs DM, Ramadan Z, Berruex F, Fuerholz A, Fay LB: Probing gender-specific metabolism differences in humans by NMR-based metabonomics. Anal.Biochem. 352, 274-281 (2006).
193. Subramanian A, Gupta A, Saxena S et al.: Proton MR CSF analysis and new software as predictors for the differentiation of meningitis in children. NMR Biomed. 18, 213-225 (2005).